Back to News
Market Impact: 0.2
ADC Therapeutics SA Announces ZYNLONTA Clinical Trial Data and Financial Restructuring
Source: Nasdaq
Healthcare & Biotech
ADC Therapeutics announced new and updated clinical-trial data for ZYNLONTA to be presented at the 68th American Society of Hematology Annual Meeting. The available text identifies LOTIS-7, a Phase 1b trial evaluating ZYNLONTA with glofitamab in relapsed or refractory disease, but provides no efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
ADCT0.40
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Cigna raises annual profit forecast on strength in health services unit
- Truist raises Zimmer Biomet stock price target on robotics progress